Li Qing, Li Chunhua, Jin Hongmei
Department of Obstetrics, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai 201700, P.R. China.
Exp Ther Med. 2020 Feb;19(2):907-912. doi: 10.3892/etm.2019.8273. Epub 2019 Dec 3.
Efficacy of allylestrenol combined with ritodrine on threatened premature labor (TPTL) and its influence on inflammatory factors in peripheral blood were investigated. A total of 206 cases of TPTL patients from 2014 to 2016 were collected in Zhongshan Hospital Affiliated to Fudan University, and 106 cases were treated with allylestrenol combined with ritodrine as a research group and 100 cases were treated with allylestrenol combined with magnesium sulfate as a control group. General information of patients was collected, and changes in the expression levels of IL-17, IL-10 and IL-6 were detected by enzyme-linked immunosorbent assay. Prolonged pregnancy time, success rate of fetal protection and average delivery time of patients were recorded. The adverse pregnancy conditions were compared, including the Apgar score of newborns, birth weight and adverse conditions, and postpartum hemorrhage volume and postpartum hospital stays in the two groups were recorded. Prolonged pregnancy time, success rate of fetal protection and average delivery time in the research group were significantly higher than those in the control group (P<0.05). After treatment, the levels of IL-17, IL-10 and IL-6 in serum of the two groups were significantly lower than those before treatment (P<0.05), and were significantly lower in the research group than in the control group (P<0.05). The average neonatal weight and Apgar score in the research group were significantly better than those in the control group (P<0.05). Postpartum hemorrhage, postpartum hospital stays and incidence rate of toxic side effects, neonatal death, malformation and asphyxia in the research group were significantly lower than those in the control group (P<0.05). Allylestrenol combined with ritodrine can significantly reduce the expression levels of IL-17, IL-10 and IL-6 in TPTL, reduce adverse pregnancy conditions, prolong gestational weeks, and has higher safety and better application value.
探讨烯丙雌醇联合利托君治疗先兆早产（TPTL）的疗效及其对外周血炎症因子的影响。收集2014年至2016年复旦大学附属中山医院206例TPTL患者，其中106例采用烯丙雌醇联合利托君治疗作为研究组，100例采用烯丙雌醇联合硫酸镁治疗作为对照组。收集患者一般资料，采用酶联免疫吸附法检测IL-17、IL-10和IL-6表达水平变化。记录患者延长妊娠时间、保胎成功率及平均分娩时间。比较两组不良妊娠情况，包括新生儿Apgar评分、出生体重及不良情况，并记录两组产后出血量及产后住院时间。研究组延长妊娠时间、保胎成功率及平均分娩时间均显著高于对照组（P<0.05）。治疗后，两组血清IL-17、IL-10和IL-6水平均显著低于治疗前（P<0.05），且研究组显著低于对照组（P<0.05）。研究组新生儿平均体重及Apgar评分均显著优于对照组（P<0.05）。研究组产后出血、产后住院时间及毒副作用发生率、新生儿死亡、畸形及窒息发生率均显著低于对照组（P<0.05）。烯丙雌醇联合利托君可显著降低TPTL患者IL-17、IL-10和IL-6表达水平，减少不良妊娠情况，延长孕周，安全性较高，应用价值较好。
